Clinical Trials on Neuroendocrine Prostate Carcinoma

Total 32292 results

National Cancer Institute (NCI)

Recruiting

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Stage IV Prostate Cancer AJCC v8 | Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Metastatic Prostate Neuroendocrine Carcinoma

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Prostate Small Cell Neuroendocrine Carcinoma | Castration-Sensitive Prostate Carcinoma

United States
Fred Hutchinson Cancer Center
Bristol-Myers Squibb

Not yet recruiting

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage III Prostate Cancer AJCC v8 | Prostate Small Cell Neuroendocrine Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Adenocarcinoma AJCC v7 | Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Prostate Adenocarcinoma With Neuroendocrine...

United States
Dana-Farber Cancer Institute
Blue Earth Diagnostics, Inc

Not yet recruiting

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

Metastatic Prostate Cancer | Advanced Prostate Cancer | Metastatic Prostate Neuroendocrine Carcinoma

United States
M.D. Anderson Cancer Center

Active, not recruiting

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Metastatic Prostate Adenocarcinoma | Castration-Resistant...

United States
Andrew J. Armstrong, MD
Bristol-Myers Squibb

Recruiting

A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP)

Metastatic Prostate Cancer | Metastatic Prostate Neuroendocrine Carcinoma

United States
M.D. Anderson Cancer Center
Janssen Pharmaceutica

Active, not recruiting

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Aggressive Variant Prostate Carcinoma | Metastatic Prostate Neuroendocrine Carcinoma | Metastatic Prostate Small Cell Carcinoma

United States
Jagiellonian University
University Hospital in Krakow

Recruiting

Clinical Application of the J-PET Scanner Prototype (JPET2Clinic)

Prostatic Neoplasms | Prostatic Hyperplasia | Prostate Cancer | Neuroendocrine Tumors | Neuroendocrine Carcinoma | Prostate Cancer Metastatic

Poland
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC

Completed

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Urothelial Carcinoma | Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Bladder Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Stage III Bladder Cancer AJCC v8 | Stage III Urethral Cancer AJCC v8 | Stage IV Bladder Cancer AJCC v8 | Stage IV Urethral... and other conditions

United States
Weill Medical College of Cornell University
Millennium Pharmaceuticals, Inc.

Completed

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

Neuroendocrine Prostate Cancer | Small Cell Prostate Cancer | Prostate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers

United States
Phanes Therapeutics

Recruiting

A Phase 1 Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3 (the SKYBRIDGE Study)

Small Cell Lung Cancer (SCLC) | Large Cell Neuroendocrine Cancer (LCNEC) | Neuroendocrine Prostate Cancer (NEPC) | Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

United States
ORIC Pharmaceuticals

Recruiting

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Metastatic Prostate Cancer | Neuroendocrine Prostate Cancer

United States
University of Western Ontario, Canada

Completed

Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples

Neuroendocrine Carcinoma (Carcinoid)

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Prostate Adenocarcinoma Without Neuroendocrine Differentiation

United States
Translational Research in Oncology
Bayer; Novartis

Withdrawn

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers (REFIT-MSS)

Soft Tissue Sarcoma | Small Cell Lung Carcinoma | Colorectal Neoplasms | Anal Squamous Cell Carcinoma | Malignant Pleural Mesothelioma | Castrate Resistant Prostate Cancer | Gastroenteropancreatic Neuroendocrine Neoplasm | Neuroendocrine Carcinoma of Prostate
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Completed

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Metastatic Prostatic Adenocarcinoma | Prostate Carcinoma Metastatic to the Bone

United States
Rahul Aggarwal
Janssen Scientific Affairs, LLC

Active, not recruiting

Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer

Prostate Cancer | Small Cell Carcinoma | Small Cell Neuroendocrine Carcinoma

United States
Jonsson Comprehensive Cancer Center
Janssen Inc.

Active, not recruiting

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

Recurrent Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma | Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer
University of Michigan Rogel Cancer Center

Recruiting

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

Pancreatic Adenocarcinoma | Pancreatic Neuroendocrine Tumor | Pancreatic Neuroendocrine Carcinoma | Adenosquamous Carcinoma | Gastrointestinal Neuroendocrine Tumor | Gastrointestinal Neuroendocrine Carcinoma | Neuroendocrine Prostate Carcinoma

United States
ValiRx Plc

Completed

Dose Finding Safety Study of VAL201 in Cancer Patients (VAL201-001)

Stage III Prostate Carcinoma | Stage IV Prostate Carcinoma
University of Washington
National Cancer Institute (NCI)

Completed

Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate Cancer | Stage IV Prostate Adenocarcinoma

United States
University of Washington
National Cancer Institute (NCI)

Completed

Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Castration Levels of Testosterone | Stage IV Prostate Adenocarcinoma

United States
University of Utah

Completed

Fluciclovine F18 PET/CT Imaging in Assessing Hormone-Naive Men With Prostate Cancer That Has Spread to the Bone

Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | Prostate Carcinoma Metastatic in the Bone

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Unknown

ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States
Emory University

Completed

Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7

United States
AbbVie

Terminated

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Glioblastoma | Medullary Thyroid Cancer | Malignant Melanoma | Other Solid Tumors | Large-Cell Neuroendocrine Carcinoma | Neuroendocrine Prostate Cancer | High Grade Gastroenteropancreatic Neuroendocrine Carcinoma | Other Neuroendocrine Carcinoma

United States
Rutgers University

Unknown

Study Investigating MEN1 and SDHD in Familial Carcinoid Tumors

Carcinoid Neuroendocrine Cancer

United States
National Cancer Institute, Naples

Completed

Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas (TENEC)

Neuroendocrine Carcinomas

Italy
University of Turin, Italy

Unknown

Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors (XELBEVOCT)

Neuroendocrine Carcinomas

Italy
Fundación de investigación HM
Syntax for Science, S.L

Recruiting

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

Neuroendocrine Tumours (NET) | Neuroendocrine Carcinomas (NEC)

Spain
National Health Research Institutes, Taiwan
National Taiwan University Hospital; Chang Gung Memorial Hospital; Kaohsiung... and other collaborators

Completed

Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients

Neuroendocrine Carcinomas

Taiwan
The Netherlands Cancer Institute

Active, not recruiting

Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin

Neuroendocrine Carcinomas

Netherlands
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Cancer Immunotherapy Trials Network

Completed

CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | Castration Levels of Testosterone

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer

Prostate Adenocarcinoma | Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage III Prostate Cancer | Stage IV Prostate Cancer

United States
Barwon Health
Australasian Gastro-Intestinal Trials Group; Deakin University; Specialised Therapeutics...

Unknown

A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas (NABNEC)

Gastrointestinal Neuroendocrine Carcinomas

Australia
Jonsson Comprehensive Cancer Center
Novartis; Stand Up To Cancer; Prostate Cancer Foundation

Active, not recruiting

Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Rigshospitalet, Denmark

Terminated

Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients

Metastatic Prostate Carcinoma

Denmark
Shanghai Proton and Heavy Ion Center

Unknown

Carbon Ion Radiotherapy in Treating Patients Undergoing Systemic Therapy for Oligo-metastatic Prostate Cancer

Metastatic Prostate Carcinoma

China
University of Washington
National Cancer Institute (NCI)

Completed

Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | PSA Progression | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy (PROMOTE)

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Hormone-Resistant Prostate Cancer

United States
Roswell Park Cancer Institute
Active Biotech AB

Completed

Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7

United States
OHSU Knight Cancer Institute
United States Department of Defense; Oregon Health and Science University

Completed

Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | PSA Progression | Castration Levels of Testosterone

United States
Mamta Parikh
National Cancer Institute (NCI); Pandomedx

Completed

Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

Biochemically Recurrent Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Active, not recruiting

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7

United States
Northwestern University

Recruiting

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Refractory Prostate Cancer | Castration-Resistant Prostatic Cancer

United States
Sir Mortimer B. Davis - Jewish General Hospital

Terminated

Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer (CROSSBOW)

Prostatic Neoplasms | Prostate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Metastatic Prostatic Adenocarcinoma | Metastatic Prostate Carcinoma in the Soft Tissue

Canada

Clinical Trials on Neuroendocrine Prostate Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations